
==== Front
J Am Acad Orthop Surg Glob Res Rev
J Am Acad Orthop Surg Glob Res Rev
JAAOS Glob Res Rev
JAAOS Glob Res Rev
JAAOS Global Research & Reviews
2474-7661
Wolters Kluwer Philadelphia, PA

JAAOSGlobal-D-24-00069
10.5435/JAAOSGlobal-D-24-00069
00010
3
009
Research Article
90-Day Complication and Readmission Rates for Geriatric Patients With Hip Fracture at Different Time Points From COVID-19 Positivity: A Database Study
https://orcid.org/0000-0001-9402-7148
Sanchez Joshua G. BA
Jiang Will M. BS
Dhodapkar Meera M. MD
Radford Zachary J. MD
Rubin Lee E. MD
https://orcid.org/0000-0002-2626-7278
Grauer Jonathan N. MD
From the Department of Orthopaedics and Rehabilitation, Yale University, New Haven, CT.
Correspondence to Dr. Grauer: jonathan.grauer@yale.edu
9 2024
18 9 2024
8 9 e24.0006921 2 2024
28 6 2024
27 7 2024
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons.
2024
American Academy of Orthopaedic Surgeons
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction:

Geriatric patients with hip fracture are at risk of having COVID-19 while needing fracture treatment. Understanding the associated risks of variable timing of COVID-19 before surgery may help direct care algorithms.

Methods:

Geriatric patients with documented hip fracture surgery were identified within the PearlDiver M157 database. Patients with a preoperative COVID-19 diagnosis were classified based on time from diagnosis to surgery: ≤ 1 week, > 1 to ≤ 4 weeks, > 4 to ≤ 7 weeks, > 7 to ≤ 10 weeks, and > 10 to ≤ 13 weeks. The association of COVID-19 diagnoses with 90-day complications was evaluated.

Results:

Overall, 263,771 patients with hip fracture were identified, of which COVID-19 within 13 weeks of surgery was documented for 976. On multivariable analysis, patients with COVID-19 infection within ≤ 1 week preoperatively demonstrated increased rates of minor adverse events (odds ratio (OR) = 1.50), all adverse events (OR = 1.59), sepsis (OR = 1.70), and pneumonia (OR = 2.35) (P ≤ 0.0007 for each). For time points greater than 1 week, there were no differences in complication rates.

Discussion:

Patients with COVID-19 within 1 week of hip fracture surgery demonstrated greater odds of 90-day complications. Reassuringly, patients with COVID-19 diagnoses more than 1 week preoperatively were not associated with increased odds of any assessed complication.

OPEN-ACCESSTRUE
Read-alongYES
==== Body
pmcAs of June 2023, SARS-CoV-2 (COVID-19) has caused an estimated number of 768,187,096 cases worldwide and 103,436,829 cases in the United States.1 While the effect of COVID-19 on medical care delivery is markedly decreasing, the question of the effect of COVID-19 diagnoses at variable time points before surgeries remains, especially for fractures that require timely surgery such as geriatric hip fractures.

For a notable period during the COVID-19 pandemic, elective surgeries were delayed for moderate lengths of time, when possible, with the hopes of minimizing perioperative adverse outcomes.2-5 However, recommendations regarding case delay after COVID-19 diagnosis have been conflicting, with recommended delays at various institutions ranging from 1 to 12 weeks after a full recovery from a confirmed COVID-19 infection.6-10

Most centers have considered geriatric hip fracture surgery to be “urgent” and, therefore, necessary, regardless of time from COVID-19 diagnosis, to facilitate mobilization, address fracture pain, and minimize bed rest morbidity.11 Compounding this matter, geriatric patients with hip fracture are at an elevated risk of COVID-19. As such, understanding the correlation of a preoperative COVID-19 diagnosis at variable timing before hip fracture surgery is of interest in this vulnerable population that is already associated with notable morbidity and mortality.12,13

Previous retrospective studies have demonstrated that patients with a perioperative COVID-19 diagnosis may have an elevated risks of death and pulmonary complications across multiple surgical specialties, with the geriatric population potentially at higher risk.8,14,15 Within orthopaedic surgery, a previous retrospective study by Levitt et al16 found perioperative COVID-19 diagnoses from 30 days before to 7 days after hip fracture surgery to be associated with a higher 30-day mortality for geriatric patients. However, this study analyzed complications and all-cause mortality in a relatively small size of 185 total COVID-19–positive patients from 46 sites in the United States.16 Furthermore, this study did not analyze the effects of variable timing from COVID-19 diagnosis to hip fracture surgery.16 In another related study, Pincavitch et al17 found increased adverse events for patients undergoing total joint arthroplasty (TJA) only within 2 weeks of a COVID-19 diagnosis.

This study used a national administrative database to evaluate the risk of 90-day postoperative adverse events after hip fracture surgery in geriatric patients with variable timing of COVID-19 diagnosis before surgery. We hypothesized that patients with a more recent COVID-19 diagnosis immediately before hip fracture surgery would have higher odds of certain postoperative complications.

Methods

Study Cohort

This study used the 2010-October 2021 PearlDiver (Colorado) M157 administrative database, a large US insurance database that encompasses records from approximately 157 million orthopaedic patients. Using PearlDiver, the data were accessed for research purposes on June 18, 2023. Owing to the anonymized and aggregated qualities of the output data, the authors of this project did not have access to information that could identify individual patients during or after data collection. As such, our institutional review board concluded that research that uses this data set is exempt from review.

Geriatric patients (older than 65 years) with an International Classification of Diseases, 9th Revision or 10th Revision (ICD-9 and ICD-10, respectively), diagnostic code of a hip fracture were identified. Those with closed femoral head/neck, intertrochanteric, and subtrochanteric fractures were included. Of patients with a diagnostic code of a hip fracture, patients who underwent surgical treatment with percutaneous screws, screw and side plate fixation, screw and intramedullary device, hemiarthroplasty, or total hip arthroplasty were selected based on Current Procedural Terminology coding.

Exclusion criteria were defined as open fractures, new diagnosis of neoplasm or non–COVID-19 infection within 90 days before the hip fracture, and patients who were not active in PearlDiver for at least 90 days postoperatively. Patient characteristics extracted from the database included age, sex, and Elixhauser Comorbidity Index (ECI, a marker of overall comorbidity burden).18,19

Patients with a documented preoperative, laboratory-confirmed COVID-19 diagnosis (ICD-10 diagnostic code: U07.1) before hip fracture surgery were identified. While patients from 2010 to October 2021 were included to increase the sample size of the COVID-19–negative control group, all COVID-19–positive patients were identified starting from April 2020 (coinciding with the release of the COVID-19 ICD-10 code). These COVID-19–positive patients were categorized based on time from COVID-19 diagnosis to hip fracture surgery as follows: ≤ 1 week, > 1 to ≤ 4 weeks, > 4 to ≤ 7 weeks, > 7 to ≤ 10 weeks, and > 10 to ≤ 13 weeks.

Postoperative Adverse Events and Readmissions

90-day postoperative complications were found with ICD coding using methods previously described.20-23 Characterized in aggregate and individually, evaluated complications included any adverse events (AAEs), severe adverse events, and minor adverse events (MAEs).

Severe adverse events were defined as at least one occurrence of surgical site infection, sepsis, venous thromboembolism ((VTE) either pulmonary embolism or deep vein thrombosis), or cardiac events (myocardial infarction or cardiac arrest). Minor adverse events were defined as at least one event of pneumonia, urinary tract infection, wound dehiscence, transfusion, acute kidney injury, or hematoma. Any adverse events were defined as at least one event of either a severe or MAE.

90-day readmissions were also identified. These were identified based on the “ADMISSIONS” code within the PearlDiver interface as previously described.22,24

Statistical Analysis

Univariable analysis was used to characterize differences between specified study groups. Continuous variables, including age and ECI, were compared using the Student t-test or one-way analysis of variance depending on the number of groups being compared. Patient sex and incidence of 90-day complications and readmissions were compared using the Pearson chi-squared test.

Multivariable logistic regression (controlling for age, sex, and ECI) was then used to determine the independent odds ratios (ORs) and 95% confidence intervals (CIs) of each examined adverse event by comparing patients in each time point category with COVID-19–negative patients.

Statistical analysis was conducted using PearlDiver Bellwether software (PearlDiver, Colorado Springs, Colorado) and GraphPad Prism 9.4.1 (GraphPad Software, San Francisco, California). For comparison of patient characteristics, significance was defined as P < 0.05. For univariate and multivariate analyses, a Bonferroni correction was applied to account for multiple comparisons (significance defined as P ≤ 0.0007).

Results

Demographics

In total, 263,771 geriatric patients undergoing hip fracture surgery were identified from 2010 to October 2021. Of these patients, COVID-19 was diagnosed within 13 weeks before surgery for 976 (2.91% of study patients from 2020 to 2021). Those with COVID-19 were, on average, older (78.49 ± 4.96 vs. 75.29 ± 3.81, P < 0.0001), were more often male (33.91% vs. 28.62%, P = 0.0003), and had higher ECI scores (9.88 ± 4.32 vs. 6.11 ± 3.96, P < 0.0001) (Table 1).

Table 1 Descriptive Characteristics of Patients Aged 65 Years or Older With and Without a Confirmed COVID-19 Diagnosis Within 13 Weeks Before Hip Fracture Surgery

	COVID-19 (−)	COVID-19 (+) Preoperatively	P	
Number of patients	262,795	976		
Age (mean ± SD)	75.29 ± 3.81	78.49 ± 4.96	<0.0001	
Sex			0.0003	
 Female	187,594 (71.38%)	645 (66.08%)		
 Male	75,201 (28.62%)	331 (33.91%)		
ECI (mean ± SD)	6.11 ± 3.96	9.88 ± 4.32	<0.0001	
ECI = Elixhauser Comorbidity Index, SD = standard deviation

Bold entries indicate statistically significant.

Patients were then grouped based on time from COVID-19 diagnosis to hip fracture surgery. COVID-19 was diagnosed at ≤ 1 week from surgery for 507 patients, > 1 to ≤ 4 weeks from surgery for 174 patients, > 4 to ≤ 7 weeks from surgery for 103 patients, > 7 to ≤ 10 weeks from surgery for 125 patients, and > 10 to ≤ 13 weeks from surgery for 67 patients (Table 2).

Table 2 Descriptive Characteristics of Patients Older Than 65 Years With a Confirmed COVID-19 Diagnosis Before Hip Fracture Surgery

	COVID-19 (+) Preoperatively (n = 976)	P	
≤ 1 Week	> 1 to ≤ 4 Weeks	> 4 to ≤ 7 Weeks	> 7 to ≤ 10 Weeks	> 10 to ≤ 13 Weeks	
No. of patients	507	174	103	125	67		
Age (mean ± SD)	78.47 ± 4.83	78.39 ± 5.14	78.83 ± 4.96	78.57 ± 5.17	78.18 ± 5.10	<0.0001	
Sex						0.9575	
 Female	336 (66.27%)	118 (67.82%)	67 (65.05%)	82 (65.60%)	42 (62.69%)		
 Male	171 (33.73%)	56 (32.18%)	36 (34.95%)	43 (34.40%)	25 (37.31%)		
ECI (mean ± SD)	9.56 ± 4.36	9.84 ± 4.19	9.89 ± 4.02	10.80 ± 4.41	10.70 ± 4.35	< 0.0001	
ECI = Elixhauser Comorbidity Index, SD = standard deviation

COVID-19 (+) patients were categorized based on the preoperative timing of the COVID-19 diagnosis.

Bold entries indicate statistically significant.

Postoperative Adverse Events and Readmissions

On univariable analysis, there were differences in aggregated AAEs, severe adverse events, MAEs, and individual adverse events (sepsis, cardiac events, pneumonia, urinary tract infection, acute kidney injury, wound dehiscence, and readmissions) between COVID-19–negative and COVID-19–positive patients within 90 days of surgery (P < 0.0007 for all) (Table 3).

Table 3 Univariable Analysesa of 90-Day Complications and Readmissions of Patients Older Than 65 Years With and Without a Confirmed COVID-19 Diagnosis Before Hip Fracture Surgery

	COVID (−) (n = 262,795)	COVID-19 (+) Preoperatively (n = 976)	P	
≤ 1 Week (n = 507)	> 1 to ≤ 4 Weeks (n = 174)	> 4 to ≤ 7 Weeks (n = 103)	> 7 to ≤ 10 Weeks (n = 125)	> 10 to ≤ 13 Weeks (n = 67)	
Any adverse events	109,877 (41.81%)	309 (60.95%)	106 (60.92%)	68 (66.02%)	81 (64.80%)	45 (67.16%)	<0.0001	
Severe adverse events​	33,838 (12.88%)	106 (20.91%)	38 (21.84%)	21 (20.39%)	29 (23.20%)	15 (22.39%)	<0.0001	
Surgical site infection	3177 (1.21%)	12 (2.37%)	< 11	< 11	< 11	< 11	0.0767	
Sepsis	10,487 (3.99%)	49 (9.67%)	19 (10.92%)	< 11	11 (8.80%)	< 11	<0.0001	
Venous thromboembolism	783 (0.30%)	50 (9.86%)	16 (9.20%)	< 11	< 11	< 11	0.0055	
Cardiac events	7894 (2.77%)	21 (4.14%)	< 11	< 11	< 11	< 11	0.0001	
Minor adverse events	97,770 (37.20%)	279 (55.03%)	99 (56.90%)	63 (61.17%)	76 (60.80%)	42 (62.69%)	<0.0001	
Pneumonia	23,399 (8.90%)	118 (23.27%)	34 (19.54%)	17 (16.50%)	21 (16.80%)	16 (23.88%)	<0.0001	
Urinary tract infection​	53,193 (20.24%)​	127 (25.05%)​	59 (33.91%)	34 (33.01%)​	41 (32.80%)	22 (32.84%)	<0.0001	
Acute kidney injury	27,067 (10.30%)​	110 (21.70%)	34 (19.54%)	24 (23.30%)	37 (29.60%)	14 (20.90%)	<0.0001	
Wound dehiscence	1815 (0.69%)	< 11	< 11	< 11	0 (0.00%)	< 11	<0.0001	
Transfusion	26,059 (9.92%)	41 (8.09%)	18 (10.35%)	11 (10.68%)	12 (9.60%)	13 (19.40%)	0.1187	
Hematoma	2499 (0.95%)	< 11	< 11	< 11	< 11	< 11	0.1186	
Readmissions	43,073 (16.39%)	122 (24.06%)	34 (19.54%)	24 (23.30%)	24 (19.20%)	15 (22.39%)	<0.0001	
a Bonferroni correction applied, P ≤ 0.0007 considered significant.

Bold entries indicate statistically significant.

On multivariable analysis, only patients who underwent hip fracture surgery within 1 week of the COVID-19 diagnosis demonstrated increased odds of 90-day complications compared with COVID-19–negative patients (Table 4, Figure 1). These complications included (in order of decreasing OR) pneumonia (OR 2.35, 95% CI [1.90, 2.90]), sepsis (OR 1.70, 95% CI [1.25, 2.28]), AAEs (OR 1.50, 95% CI [1.32, 1.91]), and MAEs (OR 1.50, 95% CI [1.25, 1.80]) (P < 0.0007 for all).

Table 4 Multivariable Analysesa (Controlling for Age, Sex, and Elixhauser Comorbidity Index (ECI)) of 90-Day Complications and Readmissions of Patients Older Than 65 Years With a Confirmed COVID-19 Diagnosis Before Hip Fracture Surgery Compared With COVID-19 (−) Patients

	COVID-19 (+) Preoperatively	P	
≤ 1 Week OR (95% CI)	P	> 1 to ≤ 4 Weeks OR (95% CI)	P	> 4 to ≤ 7 Weeks OR (95% CI)	P	> 7 to ≤ 10 Weeks OR (95% CI)	P	> 10 to ≤ 13 Weeks OR (95% CI)	
Any adverse events	1.59 (1.32, 1.91)	<0.0001	1.53 (1.12, 2.10)	0.0080	1.93 (1.28, 2.96)	0.0020	1.63 (1.13, 2.40)	0.0110	1.85 (1.11, 3.18)	0.0216	
Severe adverse events	1.36 (1.09, 1.69)	0.0054	1.41 (0.97, 2.02)	0.0633	1.29 (0.77, 2.06)	0.3072	1.39 (0.89, 2.10)	0.1260	1.31 (0.71, 2.31)	0.3577	
Surgical site infection	1.86 (0.98, 3.16)	0.0357	0.42 (0.02, 1.87)	0.3844	1.49 (0.24, 4.75)	0.5786	1.69 (0.53, 5.36)	0.3721	2.03 (0.49, 8.40)	0.3272	
Sepsis	1.70 (1.25, 2.28)	0.0005	1.95 (1.16, 3.08)	0.0072	1.65 (0.80, 3.06)	0.1390	1.31 (0.66, 2.36)	0.3959	1.58 (0.65, 3.28)	0.2651	
Venous thromboembolism	1.40 (1.03, 1.86)	0.0243	1.27 (0.73, 2.07)	0.3611	1.36 (0.66, 2.50)	0.3564	0.92 (0.43, 1.71)	0.8038	1.56 (0.44, 2.47)	0.7369	
Cardiac events	0.95 (0.59, 1.43)	0.8000	1.18 (0.56, 2.19)	0.6300	1.56 (0.65, 3.15)	0.2600	1.68 (0.82, 3.07)	0.1190	1.56 (0.54, 3.55)	0.3450	
Minor adverse events​	1.50 (1.25, 1.80)	<0.0001	1.57 (1.15, 2.14)	0.0043	1.90 (1.27, 2.86)	0.0020	1.67 (1.16, 2.43)	0.0067	1.84 (1.11, 3.11)	0.0188	
Pneumonia	2.35 (1.90, 2.90)	<0.0001	1.83 (1.23, 2.66)	0.0019	1.46 (0.83, 2.42)	0.1613	1.36 (0.82, 2.14)	0.2125	2.12 (1.15, 3.69)	0.0108	
Urinary tract infection	1.05 (0.85, 1.28)	0.6523	1.58 (1.14, 2.17)	0.0049	1.54 (1.01, 2.32)	0.0420	1.41 (0.96, 2.05)	0.0737	1.45 (0.85, 2.40)	0.1631	
Acute kidney injury	1.39 (1.11, 1.73)	0.0036	1.19 (0.80, 1.73)	0.3786	1.46 (0.89, 2.32)	0.1170	1.81 (1.20, 2.69)	0.0038	1.11 (0.58, 1.99)	0.7363	
Wound dehiscence	1.65 (0.75, 3.11)	0.1634	2.95 (1.04, 6.51)	0.0178	1.99 (0.33, 6.34)	0.3359	0.00 (0.00, 0.00)	0.8970	2.73 (0.45, 8.82)	0.1641	
Transfusion	0.67 (0.48, 0.92)	0.0170	0.85 (0.50, 1.35)	0.5110	0.91 (0.46, 1.65)	0.7810	0.72 (0.37, 1.27)	0.2910	1.67 (0.86, 3.02)	0.1090	
Hematoma	1.54 (0.74, 2.81)	0.2010	1.44 (0.36, 3.82)	0.5300	1.66 (0.27, 5.27)	0.4790	1.88 (0.46, 4.99)	0.2840	1.13 (0.06, 5.13)	0.9070	
Readmissions	1.23 (0.99, 1.51)	0.0554	0.89 (0.60, 1.30)	0.5689	1.15 (0.71, 1.81)	0.5578	0.78 (0.49, 1.22)	0.2954	0.95 (0.51, 1.68)	0.8638	
Cohorts were categorized based on timing of the COVID-19 diagnosis.

a Bonferroni correction applied, P ≤ 0.0007 considered significant.

Bold entries indicate statistically significant.

Figure 1 Plots demonstrating risk of 90-day adverse events after hip fracture surgery for geriatric patients with COVID-19 versus without. Forest plots of odds ratios with 95% confidence intervals in the COVID-19–positive cohorts relative to the COVID-19–negative cohort are shown. COVID-19–positive cohorts were categorized based on timing of the COVID-19 diagnosis compared with surgery (as shown in the title of the respective plots). Black bars are statistically significant while gray bars are not. CI = confidence interval.

No notable differences in 90-day adverse events were observed for patients who received hip fracture surgery after 1 week to the COVID-19 diagnosis (Table 4, Figure 1). 90-day readmission rates were not statistically different for patients in any timing category of COVID-19 diagnosis compared with COVID-19–negative patients.

Discussion

The correlation of recent COVID-19 diagnosis and perioperative adverse events is not fully defined. Understanding this correlation is very pertinent to geriatric patients with hip fractures for whom surgery is considered necessary and timely.12,25,26 Those with COVID-19 within 1 to 12 weeks of surgery have been considered to be at greater risk of perioperative complications.6,7,9,10,16,17,27 As such, this study sought to define the complication risks in a large population undergoing hip fracture surgery with varied timing of preoperative COVID-19 infection.

The number of patients with COVID-19 within 13 weeks of hip fracture surgery was relatively small, comprising only 976 cases or 2.91% of surgeries from 2020 to 2021. This low incidence underscores the value of using a large, national database to accrue a population sufficiently powered to address the questions at hand.

Patients with COVID-19 within 13 weeks of hip fracture surgery were older, had higher ECI scores (indicating increased illness severity), and were more likely to be male than those without a COVID-19 diagnosis. These findings align with previous literature that identified older age, male sex, and underlying chronic comorbid conditions as risk factors of COVID-19 in adults.28,29

By multivariate analysis, those with a COVID-19 diagnosis within 1 week of hip fracture surgery were at greater odds of pneumonia (OR 2.35) and sepsis (OR 1.70). These individual events contributed to the higher odds of AAEs (OR 1.59) and MAEs (OR 1.50). These findings follow previous research that associated preoperative COVID-19 infection with postoperative pulmonary complications and sepsis after major elective surgery.27,30,31 Within orthopaedic surgery, specifically, Pincavitch et al17 reported that COVID-19 infection only within 14 days before TJA also increased the risk of pneumonia and sepsis. Furthermore, Galivanche et al27 demonstrated that a COVID-19 diagnosis within 2 weeks of hip fracture surgery was associated with increased risk of any, serious, and MAEs. However, this study did not consider the timing of COVID-19 diagnoses and evaluated complications only within 30 days after surgery.27 Overall, the findings of this study are consistent with previous literature and suggest that a COVID-19 infection only within 7 days of hip fracture surgery may place patients at higher risk of pneumonia, sepsis, and aggregated adverse events.

There are pertinent negatives for those with COVID-19 diagnosed within 1 week of hip fracture surgery. Critically, this investigation found no notable difference in the rate of VTE, surgical site infection, or cardiac events in any timing category of COVID-19–positive patients compared with COVID-19–negative patients. Regarding VTE, this study parallels the previously mentioned work (Pincavitch et al) that found no difference in the rate of VTE in patients with COVID-19 infection within 90 days of TJA.17 However, both these findings contradict previous literature that associates VTE with COVID-19 sequelae.16,27,32 With these contrasting findings, additional prospective studies and research are needed to provide robust evidence-based treatment for COVID-19–positive patients with hip fracture.

The lack of complications associated with COVID-19 more than 1 week from hip fracture surgery is a very pertinent finding. Of course, the number and severity of COVID-19 cases have declined after the decreased intensity of the pandemic. Nonetheless, this is thought to only decrease the associated morbidity with surgery in patients with a recent COVID-19 infection and underscores the safety of surgeries done more than 1 week after diagnosis.

This investigation has typical limitations associated with retrospective administrative databases, including concerns regarding data quality and potential unaccounted-for confounding variables. These variables include differences in procedural details, surgeon experience, and the interval between fracture occurrence and surgery. Because data capture of COVID-19 information relied on ICD-10 coding (U07.1), the retrospective design of this study allows for potential error surrounding the diagnosis and time line of COVID-19 and could not account for the severity of COVID-19 diagnoses. In addition, while some of the COVID-19 cases may have been missed based on incorrect administrative coding, these cases would not markedly affect the larger non-COVID-19 patient group. Moreover, this study does not allow for the evaluation of COVID-19 vaccination.

Important to note, the control group of COVID-19–negative patients reflects data from 2010 to October 2021 rather than coinciding with the onset of COVID-19–specific coding in April 2020. This extended time frame was chosen to mitigate the effect of confounding variables by increasing the sample size of COVID-19–negative patients. Furthermore, patients included in this study underwent either fixation or arthroplasty procedures, each associated with different postoperative risks. However, a direct comparison of these surgical methods was not feasible because of insufficient power. Previous research has also demonstrated shifts in hip fracture treatment preferences since 2010, notably the increased use of intramedullary nails over sliding hip screws.33 There has also been a general decrease in healthcare utilization factors, such as in-hospital length of stay, mortality, and complication rates after hip fracture surgery since 2010.33-35 Finally, although this study uses a large overall population of COVID-19–positive patients, individual study groups remain relatively small. Despite these limitations, this study presents valuable insights into the evolving landscape of geriatric hip fracture treatment beyond 2020, where much of the previous literature ends.

Conclusion

In conclusion, only patients with a perioperative COVID-19 infection within 1 week of hip fracture surgery demonstrated greater odds of 90-day adverse events and may require specific counseling/care algorithms. Reassuringly, those with COVID-19 diagnosis more than 1 week preoperatively were not associated with increased odds of any of the assessed 90-day adverse events. These data can aid patient counseling and risk stratification for geriatric patients with hip fracture, with potential extrapolation to the surgical treatment of other geriatric injuries. Moreover, these findings highlight the need for additional research to characterize the risks associated with varied timing of COVID-19 diagnoses across different patient populations and procedures.

Financial disclosures/conflicts of interests: Ms. Meera M Dhodapkar (Richard K. Gershon, M.D. Fund at Yale University School of Medicine, Associate Editor Visual Abstracts North American Spine Society Journal)

Dr. Rubin or an immediate family member has received royalties from Johns Hopkins University Press, SLACK Incorporated; serves as a paid consultant to Convatec, Depuy, Thompson Surgical Instruments, and Innovative Medical Products; Editorial/Governing Board Arthroplasty Today, Journal of Arthroplasty, and Reconstructive Review. Dr. Grauer or an immediate family member serves as a board member, owner, officer, or committee member of North American Spine Society. None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Mr. Sanchez, Mr. Jiang, and Dr. Radford.
==== Refs
References

1. WHO: WHO coronavirus (COVID-19) disease dashboard. 2023.
2. Brown TS Bedard NA Rojas EO : The Effect of the COVID-19 Pandemic on Electively Scheduled Hip and Knee Arthroplasty Patients in the United States. J Arthroplasty 2020;35 (7S ):S49-S55.32376163
3. Brown TS Bedard NA Rojas EO : The effect of the COVID-19 pandemic on hip and knee arthroplasty patients in the United States: A multicenter update to the previous survey. Arthroplast Today 2021;7 :268-272.33294537
4. Diaz A Sarac BA Schoenbrunner AR Janis JE Pawlik TM : Elective surgery in the time of COVID-19. Am J Surg 2020;219 :900-902.32312477
5. Sarac NJ Sarac BA Schoenbrunner AR : A review of state guidelines for elective orthopaedic procedures during the COVID-19 outbreak. J Bone Joint Surg Am 2020;102 :942-945.32282419
6. American Society of Anesthesiologists: ASA and APSF joint statement on elective surgery and anesthesia for patients after COVID-19 infection. 2020.
7. American Society of Anesthesiologists: ASA and APSF joint statement on elective surgery/procedures and anesthesia for patients after COVID-19 infection. 2022.
8. Jonker PKC van der Plas WY Steinkamp PJ : Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: A Dutch, multicenter, matched-cohort clinical study. Surgery 2021;169 :264-274.33158548
9. Kougias P Sharath SE Zamani N Brunicardi FC Berger DH Wilson MA : Timing of a major operative intervention after a positive COVID-19 test affects postoperative mortality: Results from a nationwide, procedure-matched analysis. Ann Surg 2022;276 :554-561.35837893
10. COVIDSurg CollaborativeGlobalSurg CollaborativeGlobalSurg: Timing of surgery following SARS-CoV-2 infection: An international prospective cohort study. Anaesthesia 2021;76 :748-758.33690889
11. Switzer JA O'Connor MI : AAOS management of hip fractures in older adults evidence-based clinical practice guideline. J Am Acad Orthop Surg 2022;30 :e1297-e1301.36200818
12. Schnell S Friedman SM Mendelson DA Bingham KW Kates SL : The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil 2010;1 :6-14.23569656
13. Katsoulis M Benetou V Karapetyan T : Excess mortality after hip fracture in elderly persons from europe and the USA: The CHANCES project. J Intern Med 2017;281 :300-310.28093824
14. COVIDSurg Collaborative: Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: An international cohort study. Lancet 2020;396 :27-38.32479829
15. Glasbey JC Nepogodiev D Simoes JF : Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study. J Clin Oncol 2021;39 :66-78.33021869
16. Levitt EB Patch DA Mabry S : Association between COVID-19 and mortality in hip fracture surgery in the national COVID cohort collaborative (N3C): A retrospective cohort study. J Am Acad Orthop Surg Glob Res Rev 2022;6 :e21.00282.
17. Pincavitch JD Pisquiy JJ Wen S : Thirty-day mortality and complication rates in total joint arthroplasty after a recent COVID-19 diagnosis: A retrospective cohort in the national COVID cohort collaborative (N3C). J Bone Joint Surg Am 2023;105 :1362-1372.37352338
18. Menendez ME Neuhaus V van Dijk CN Ring D : The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res 2014;472 :2878-2886.24867450
19. Austin SR Wong YN Uzzo RG Beck JR Egleston BL : Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work. Med Care 2015;53 :e65-e72.23703645
20. Sanchez JG Jiang WM Dhodapkar MM Radford ZJ Rubin LE Grauer JN : Total hip arthroplasty in patients who have factor V leiden: Elevated risks isolated to venous thromboembolism events. J Arthroplasty 2024. doi: 10.1016/j.arth.2024.05.083.
21. Jiang W Sanchez JG Dhodapkar MM Radford ZJ Rubin LE Grauer JN : Outcomes following total hip arthroplasty in patients who have von willebrand disease depend on postoperative anticoagulation. The J Arthroplasty 2024;39 :2088-2093.38462141
22. Dhodapkar MM Halperin SJ Joo PY : Weight loss makes the difference: Perioperative outcomes following posterior lumbar fusion in patients with and without weight loss following bariatric surgery. Spine J 2023;23 :1506-1511.37302416
23. Gouzoulis MJ Kammien AJ Caruana DL Wiznia DH Grauer JN : Hidradenitis suppurativa leads to increased risk of wound-related complications following total joint arthroplasty. Arthroplast Today 2022;16 :169-174.35789782
24. Gouzoulis MJ Kammien AJ Zhu JR Gillinov SM Moore HG Grauer JN : Single-level posterior lumbar fusions in patients with Ehlers Danlos Syndrome not found to be associated with increased postoperative adverse events or five-year reoperations. N Am Spine Soc J 2022;11 :100136.35783003
25. Ikpeze TC Mohney S Elfar JC : Initial preoperative management of geriatric hip fractures. Geriatr Orthop Surg Rehabil 2017;8 :64-66.28255514
26. Meyer JR Earnest RE Johnson BM Steffensmeier AM Vyas DA Laughlin RT : Implementation of a multidisciplinary preoperative protocol for geriatric hip fractures improves time to surgery at a level III trauma center. Geriatr Orthop Surg Rehabil 2023;14 :21514593231181991.37325698
27. Galivanche AR Mercier MR Schneble CA : Clinical characteristics and perioperative complication profiles of COVID-19-positive patients undergoing hip fracture surgery. J Am Acad Orthop Surg Glob Res Rev 2021;5 :e21.00104.
28. Fauci AS Lane HC Redfield RR : COVID-19 - navigating the uncharted. N Engl J Med 2020;382 :1268-1269.32109011
29. Zhang JJ Dong X Liu GH Gao YD : Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol 2023;64 :90-107.35044620
30. COVIDSurg Collaborative: Mortality and pulmonary complications in emergency general surgery patients with COVID-19: A large international multicenter study. J Trauma Acute Care Surg 2022;93 :59-65.35195098
31. Deng JZ Chan JS Potter AL : The risk of postoperative complications after major elective surgery in active or resolved COVID-19 in the United States. Ann Surg 2022;275 :242-246.34793348
32. Abou-Ismail MY Diamond A Kapoor S Arafah Y Nayak L : The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194 :101-115.32788101
33. Fluck B Yeong K Lisk R : Changes in characteristics and outcomes of patients undergoing surgery for hip fractures following the initiation of orthogeriatric service: Temporal trend analysis. Calcif Tissue Int 2022;110 :185-195.34448887
34. Remily EA Mohamed NS Wilkie WA : Hip fracture trends in America between 2009 and 2016. Geriatr Orthop Surg Rehabil 2020;11 :2151459320929581.32566366
35. Jiang Y Luo Y Lyu H : Trends in comorbidities and postoperative complications of geriatric hip fracture patients from 2000 to 2019: Results from a hip fracture cohort in a tertiary hospital. Orthop Surg 2021;13 :1890-1898.34431625
